Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;4(12):1551-1577.
doi: 10.3390/ph4121551.

Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix

Chandra Shekhar Boosani  1 , Yakkanti A Sudhakar
Affiliations

Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix

Chandra Shekhar Boosani et al. Pharmaceuticals (Basel). 2011 Dec.

Abstract

Angiogenesis, a neovascularization process induced from the existing parent blood vessels, is a prerequisite for many physiological and pathological conditions. Under physiological conditions it is regulated by a balance between endogenous angioinhibitors and angioactivators, and an imbalance between them would lead to pathological conditions such as cancer, age-related macular degeneration (AMD), diabetic retinopathy, cardiovascular diseases, etc. Several proteolytically generated endogenous molecules have been identified which exhibit angioinhibition and/or antitumor activities. These angioinhibitors interact with endothelial and tumor cells by binding to distinct integrins and initiate many of their intracellular signaling mechanisms regulating the cell survival and or apoptotic pathways. The present review will focus on the extracellular matrix derived angioinhibitors, and their mechanisms of actions that point to the clinical significance and therapeutic implications.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of extracellular matrix derived endogenous angioinhibitors.
Figure 2
Figure 2
Illustration of non-collagenous extracellular matrix derived angioinhibitors.
Figure 3
Figure 3
Illustration of vasoinhibin mediated angioinhibitory signaling.
See this image and copyright information in PMC

References

    1. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971;285:1182–1186. - PubMed
    1. Abdollahi A., Lipson K.E., Sckell A., Zieher H., Klenke F., Poerschke D., Roth A., Han X., Krix M., Bischof M., et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003;63:8890–8898. - PubMed
    1. Filleur S., Volpert O.V., Degeorges A., Voland C., Reiher F., Clezardin P., Bouck N., Cabon F. In vivo mechanisms by which tumors producing thrombospondin-1 bypass its inhibitory effects. Genes Dev. 2001;15:1373–1382. - PMC - PubMed
    1. Filleur S., Courtin A., Ait-Si-Ali S., Guglielmi J., Merle C., Harel-Bellan A., Clezardin P., Cabon F. siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003;63:3919–3922. - PubMed
    1. Fernando N.T., Koch M., Rothrock C., Gollogly L.K., D'Amore P.A., Ryeom S., Yoon S.S. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res. 2008;14:1529–1539. - PubMed

LinkOut - more resources